Shah, H., Chen, H., Pan, X.-Z., Metjian, A., Brodsky, R. A., Braunstein, E. M., & Chaturvedi, S. (2022). C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy. Blood Adv, 6(23), 6071–6074. https://doi.org/10.1182/bloodadvances.2022008395

Shah, Hridaya, Hang Chen, Xiang-Zuo Pan, Ara Metjian, Robert A. Brodsky, Evan M. Braunstein, and Shruti Chaturvedi. “C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy.” Blood Adv 6, no. 23 (December 13, 2022): 6071–74. https://doi.org/10.1182/bloodadvances.2022008395.

Shah H, Chen H, Pan X-Z, Metjian A, Brodsky RA, Braunstein EM, et al. C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy. Blood Adv. 2022 Dec 13;6(23):6071–4.

Shah, Hridaya, et al. “C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy.” Blood Adv, vol. 6, no. 23, Dec. 2022, pp. 6071–74. Pubmed, doi:10.1182/bloodadvances.2022008395.

Shah H, Chen H, Pan X-Z, Metjian A, Brodsky RA, Braunstein EM, Chaturvedi S. C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy. Blood Adv. 2022 Dec 13;6(23):6071–6074.